Description

The National Cancer Institute (NCI) Working Group on chronic lymphocytic leukemia developed criteria for evaluating the response of patients with B-cell CLL to therapy.


 

Complete response - all of the following:

(1) physical examination of lymph nodes, liver and/or spleen: normal (no lymphadenopathy; spleen and liver not palpable)

(2) constitutional symptoms: none

(3) lymphocyte count <= 4,000 per µL

(4) neutrophil count >= 1,500 per µL

(5) platelet count > 100,000 per µL

(6) hemoglobin (untransfused) > 11 g/dL

(7) bone marrow examination: < 30% lymphocytes and no nodules; if marrow hypocellular repeat in 2 weeks

(8) duration of response >= 2 months

 

Partial response:

(1) physical examination of lymph nodes, liver and/or spleen: >= 50% decrease (if abnormal prior to treatment)

(2) lymphocyte count: >= 50% decrease in absolute count

(3) one or more of the following:

(3a) neutrophil count >= 1,500 per µL (in 1988 included 50% improvement)

(3b) platelet count > 100,000 per µL (in 1988 included 50% improvement)

(3c) hemoglobin (untransfused) > 11 g/dL

(3d) hemoglobin >= 50% improvement

(4) duration of response >= 2 months

 

Progressive disease - one or more of the following:

(1) physical examination of lymph nodes, liver and/or spleen: >= 50% increase, OR new

(2) circulating lymphocytes: >= 50% increase in absolute count

(3) development of Richter's syndrome

(4) development of prolymphocytic leukemia with > 55% prolymphocytes

 

Stable disease: all others (do not meet any of the above criteria)

 


To read more or access our algorithms and calculators, please log in or register.